Research programme: anticancer immunoconjugates - Onconova Therapeutics

Drug Profile

Research programme: anticancer immunoconjugates - Onconova Therapeutics

Alternative Names: ON-013100; ON-01500

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Onconova Therapeutics
  • Class Small molecules; Sulfones
  • Mechanism of Action Cell cycle inhibitors; Signal transducing adaptor protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
  • 21 Apr 2015 Pharmacodynamics data from preclinical studies in Cancer presented at the Annual Meeting of American Association of Cancer Research (AACR-2015)
  • 08 Sep 2010 Onconova - immunoconjugate therapeutics - Onconova is available for licensing.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top